Glazer 1990a.

Methods	Allocation: "randomly assigned", not described Blindness: double, "identical capsules" Design: parallel groups Setting: outpatients, USA Duration: 2 weeks
Participants	Diagnosis: schizophrenia or schizoaffective disorder with TD (operational criteria) and criterion for withdrawal‐exacerbated TD N = 18 Age: mean 47 years Sex: 55% women History: duration of TD at least 3 months; "Patients had been receiving at least a year of continuous treatment with antipsychotics other than molindone or haloperidol"; "After a week on one of these two medications at pre‐established doses equivalent to that of the pre‐study neuroleptic"
Interventions	Antipsychotic medications were tapered over a 7‐10 d period and then withdrawn, with single‐blind substitution of placebo for 7‐14 d. Study medication was administered when there was a demonstrable increase in involuntary movements. 1. Molindone: dose 75 mg (mean) during the first week (100% of pre‐trial dose equivalent) and 145 mg (mean) (200% of pre‐trial dose equivalent) during the second week. N = 9 2. Haloperidol: dose 19.3 mg (mean) (100% of pre‐trial dose equivalent) during the first week and 34.3 mg (mean) (200% of pre‐trial dose equivalent) during the second week. N = 9 Concomitant medications: psychoactive medications including antiparkinsonism agents, within 6 months before study entry were not allowed
Outcomes	Clinical improvement: AIMS Leaving the study early Unable to use ‐ Mental state: BPRS Websters Parkinson Rating Scale: no usable data
Notes	Sponsorship source: supported in part by a grant from E.I. DuPont Pharmaceutical Company and National Institute of Mental Health Grant
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomly assigned to receive either molindone or haloperidol in a double‐blind fashion", further details not reported
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"double blind" "Medication was supplied in identical‐appearing red capsules containing 25 mg and 5 mg, respectively, of molindone and haloperidol"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	"double‐blind". Details of blinding of outcome assessment not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomised participants completed the trial
Selective reporting (reporting bias)	Unclear risk	Unclear if psychiatric symptoms, dyskinetic movements and parkinsonism measured by BPRS and Webster Parkinsonism Rating Scale were defined as outcomes. Only AIMS results were reported.
Other bias	High risk	The two groups were comparable except for a greater past hospitalisation duration in the molindone as compared with haloperidol‐treated group